d-mannosuria levels measured 1 h after d-mannose intake can select out favorable responders: A pilot study.
d-mannose
recurrent urinary tract infections
women
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
19
09
2022
received:
14
06
2022
accepted:
22
09
2022
pubmed:
3
10
2022
medline:
3
1
2023
entrez:
2
10
2022
Statut:
ppublish
Résumé
d-mannose is used as preventive measure against recurrent urinary tract infections (RUTIs). We studied d-mannosuria after a challenge test to identify favorable responders that could be targeted for long-term preventive therapy. Following institutional review board approval, women attending a specialized tertiary care center urology clinic with a history of RUTIs were invited to participate by providing a urine sample (baseline), followed by the intake of home-dose d-mannose, and a second urine sample 1 h later (post). Urine samples were processed according to a d-mannosuria assay technique reported previously by our group. d-mannose concentrations were normalized to urinary creatinine. From July 2020 to March 2021, 26 patients met study criteria. Thirteen had a lower or unchanged ratio of baseline to post d-mannose, whereas 13 were responders. Among 19 taking 2 g, 12 had a lower or unchanged trend and 7 were responders with >20% increase in the d-mannose/creatinine ratio. Comparison of urinary baseline d-mannose/creatinine ratios was significantly different between the responder (mean = 0.337 ± 0.158) and nonresponder (mean = 0.692 ± 0.444; p = 0.016) groups. Urinary post d-mannose/creatinine ratios did not significantly differ between the two groups (p = 0.46). d-mannose-naïve patients had few responders, and age and urinary creatinine did not affect the findings. This preliminary study on d-mannose challenge tests indicates a urine response if urinary d-mannose/creatinine ratio is low, which it was in some women with a history of RUTIs.
Sections du résumé
BACKGROUND
d-mannose is used as preventive measure against recurrent urinary tract infections (RUTIs). We studied d-mannosuria after a challenge test to identify favorable responders that could be targeted for long-term preventive therapy.
MATERIAL AND METHODS
Following institutional review board approval, women attending a specialized tertiary care center urology clinic with a history of RUTIs were invited to participate by providing a urine sample (baseline), followed by the intake of home-dose d-mannose, and a second urine sample 1 h later (post). Urine samples were processed according to a d-mannosuria assay technique reported previously by our group. d-mannose concentrations were normalized to urinary creatinine.
RESULTS
From July 2020 to March 2021, 26 patients met study criteria. Thirteen had a lower or unchanged ratio of baseline to post d-mannose, whereas 13 were responders. Among 19 taking 2 g, 12 had a lower or unchanged trend and 7 were responders with >20% increase in the d-mannose/creatinine ratio. Comparison of urinary baseline d-mannose/creatinine ratios was significantly different between the responder (mean = 0.337 ± 0.158) and nonresponder (mean = 0.692 ± 0.444; p = 0.016) groups. Urinary post d-mannose/creatinine ratios did not significantly differ between the two groups (p = 0.46). d-mannose-naïve patients had few responders, and age and urinary creatinine did not affect the findings.
CONCLUSION
This preliminary study on d-mannose challenge tests indicates a urine response if urinary d-mannose/creatinine ratio is low, which it was in some women with a history of RUTIs.
Substances chimiques
Mannose
PHA4727WTP
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-55Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Al-Badr A, Al-Shaikh G. Recurrent urinary tract infections management in women: a review. Sultan Qaboos Univ Med J. 2013;13(3):359-367.
Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151(12):1194-1205.
Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289.
Kyriakides R, Jones P, Somani BK. Role of D-mannose in the prevention of recurrent urinary tract infections: evidence from a systematic review of the literature. Eur Urol Focus. 2020;7:1166-1169.
Domenici L, Monti M, Bracchi C, et al. D-mannose: a promising support for acute urinarytract infections in women. A pilot study. EurRev Med Pharmacol Sci. 2016;20(13):2920-2925.
Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. Efficacy of combined antibacterial-prebiotic therapy in combination with D-mannose in women with uncomplicated lower urinary tract infection. Urologiia. 2019;(6):38-43.
Phé V, Pakzad M, Haslam C, et al. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn. 2017;36(7):1770-1775.
Porru D, Parmigiani A, Tinelli C, et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clin Urol. 2014;7(3):208-213.
Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79-84.
Altarac S, Papes D. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int. 2014;113(1):9-10.
Alton G, Hasilik M, Niehues R, et al. Direct utilization of mannose for mammalian glycoprotein biosynthesis. Glycobiology. 1998;8(3):285-295.
Mehta I, Zimmern P, Reitzer L. Enzymatic assay of D-mannose from urine. Bioanalysis. 2018;10(23):1947-1954.
Malik RD, Wu YR, Zimmern PE. Definition of recurrent urinary tract infections in women: which one to adopt? Female Pelvic Med Reconstr Surg. 2018;24(6):424-429.
Toora BD, Rajagopal G. Measurement of creatinine by jaffe's reaction-determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum. Indian J Exp Biol. 2002;40(3):352-354.
Sharma V, Ichikawa M, Freeze HH. Mannose metabolism: more than meets the eye. Biochem Biophys Res Commun. 2014;453(2):220-228.
Hu X, Shi Y, Zhang P, Miao M, Zhang T, Jiang B. D-mannose: properties, production, and applications: an overview. Compr Rev Food Sci Food Saf. 2016;15(4):773-785.
Michaels EK, Chmiel JS, Plotkin BJ, Schaeffer AJ. Effect of D-mannose and d-glucose on Escherichia coli bacteriuria in rats. Urol Res. 1983;11(2):97-102.
Liu H, Gu R, Zhu Y, et al. D-mannose attenuates bone loss in mice via treg cell proliferation and gut microbiota-dependent anti-inflammatory effects. Ther Adv Chronic Dis. 2020;11:2040622320912661.
Torretta S, Scagliola A, Ricci L, et al. D-mannose suppresses macrophage IL-1beta production. Nat Commun. 2020;11(1):6343.
Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265 e1-265 e13.
Toyota S, Fukushi Y, Katoh S, Orikasa S, Suzuki Y. [Anti-bacterial defense mechanism of the urinary bladder. Role of mannose in urine]. Nihon Hinyokika Gakkai Zasshi. 1989;80(12):1816-1823.
Shoemaker JD, Elliott WH. Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. J Chromatogr. 1991;562(1-2):125-138.